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0929-6646/Copyright ª 2014, ElsevierBackground/Purpose: Long-term exposure to opiates induces tolerance to the analgesic effect
and dependence. In recent years, several studies have been conducted to find agents that can
prevent the development of these two phenomena. The aim of the present study is to evaluate
the effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in-
hibitor, on morphine-induced tolerance and withdrawal symptoms.
Methods: Groups of male rats received daily morphine [for induction of tolerance (10 mg/kg)
and for induction of dependence (additive doses: 5 mg/kg/12 h, 10 mg/kg/12 h, 15 mg/kg/
12 h, 20 mg/kg/12 h, and 25 mg/kg/12 h)] in combination with propylene glycol or simvastatin
[5 mg/kg, per os (p.o.), 10 mg/kg, p.o., and 20 mg/kg, p.o.]. Next, the nociception was as-
sessed by the plantar test apparatus. The latency was recorded when the animal responded
to the light stimulus. The animals received additional doses of morphine for 9 days in order
to induce dependency. One hour after the last dose of the morphine injection, naloxone
was administered and withdrawal symptoms were recorded for 1 hour.
Results: The results of the present study showed that chronic morphine administration induced
tolerance to the analgesic effect for 19 days, whereas simvastatin (20 mg/kg, p.o.) delayed the
day of the established tolerance by 5 days. The administration of simvastatin also prevented
the morphine-induced shift to the right of the 50% effective dose (ED50) in the doseeresponseave no conflicts of interest relevant to this article.
t of Physiology and Pharmacology, Faculty of Medicine, Kurdistan University of Medical Sciences,
h@gmail.com (K. Hassanzadeh).
to this study.
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400 F. Ghasemi et al.curve. Furthermore, the results showed that simvastatin decreased the total withdrawal score
significantly.
Conclusion: We found that simvastatin attenuated morphine-induced tolerance and with-
drawal symptoms.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
For thousands of years, opioids have been widely used for
the management of severe/acute and chronic pain. Opioid
antinociceptive tolerance and dependence are the most
serious problems associated with continued administration
of morphine and other opioids. Indeed, opioid anti-
nociceptive tolerance manifests as a shift of the dose
response curve to the right and loss of the analgesic effect
of the opioid. The development of tolerance and depen-
dence to opioids limits their therapeutic use. Hence, many
attempts have been done to identify the involved mecha-
nisms and the possible agents that can prevent these two
phenomena.
In this respect, many mechanisms have been suggested
in the occurrence of opioid antinociceptive tolerance and
dependence including m-opioid receptor oligomerization or
downregulation,1 regulation of m-opioid receptor/Gi-
protein coupling,2 G protein uncoupling from opioid re-
ceptors,3 activation of excitatory amino acid receptors
[i.e., N-methyl-D-aspartate (NMDA)] and neuron plas-
ticity,4,5 activation of the apoptosis cascade, and glial
activation with increasing inflammatory cytokine
expression.6
Among the above mechanisms, the role of the m-opioid
receptor has been studied by researchers. In this regard,
Chou et al2 indicated that ultra-low-dose naloxone restores
the antinociceptive effect of morphine in morphine-
tolerant rats, possibly by regulating the m-opioid recep-
tor/Gi-protein.
In addition, following chronic morphine treatment,
microglia and astrocytes are activated and increase the
secretion of inflammatory cytokines and other media-
tors.6e8 Activated glia produce and release proin-
flammatory cytokines such as tumor necrosis factor alpha
(TNF-a), interleukin-1beta (IL-1b), IL-6, prostaglandins,
excitatory amino acids (glutamate and aspartate), and ni-
tric oxide.9,10 These inflammatory products directly in-
crease neuronal excitability, sensitize pain transmission
neurons, increase the blockade of glutamate transporters,
and upregulate a-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) and NMDA receptors. These pro-
cesses lead to the induction of morphine tolerance and
dependence.8,9,11
In vitro studies indicated that exposure to opioid re-
ceptor agonists increased their vulnerability to death
through apoptotic mechanisms.12,13 Previous studies also
showed that both morphine tolerance and the associated
neuronal apoptosis shared a common cellular mechanism.
In view of these findings, it was reported that NMDA re-
ceptor antagonists and neuroprotective agents blockedboth tolerance and apoptosis.14 During the past decade,
evidence has emerged that statins have neuroprotective
effects.15,16 Statins, which are 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors, are
commonly used as cholesterol-lowering drugs.17,18 It was
also reported that the intake of statins was associated with
a decrease in the incidence of Alzheimer’s disease (AD) and
reduces the production of amyloid-beta (Ab) peptide
in vitro.15e17 In addition, statins have beneficial effects in
the Parkinson’s disease (PD).19,20
Simvastatin upregulates the gene expression and protein
levels of the major antiapoptotic protein Bcl-2 in vivo and
in vitro; this process is independent of the mevalonate/
isoprenoid/cholesterol pathway.21
Furthermore, Zacco et al22 suggest that the statins
disable the NMDA receptor through disruption of lipid rafts.
Recent in vitro evidence also confirms that simvastatin
reduces the association of the NMDA receptor with the lipid
rafts.22,23 Several in vitro and in vivo studies provide evi-
dence that statins activate the neuroprotective protein
kinase b (PKB/Akt) as well. Moreover, activation of PKB/Akt
by statins has been attested in endothelial and progenitor
cells.24,25
Following on from the above-mentioned research, the
present study investigates the effect of simvastatin on
morphine tolerance and dependence.Materials and methods
Animals
Male Wistar rats (n Z 128) weighing 250e300g were pur-
chased from Razi Institute (Tehran, Iran). The animals
were housed in a temperature-controlled room (25  2C)
in a standard polypropylene cage (4 rats per cage), and
kept on a 12 h light/dark cycle (lights on at 8:00 AM) with
free access to food and water ad libitum (except for a
brief time during the testing). They were randomly divided
into several experimental groups; each group comprised
eight animals. Two days prior to the experiment, the ani-
mals were habituated to the testing environment including
transferring to the experimental laboratory, weighing, and
handling in order to adapt them to the environment and
the procedures, and to minimize the nonspecific stress
response. All the experiments were in accordance with the
Guide for the Care and Use of Laboratory Animals (Na-
tional Institutes of Health Publication No. 85e23, revised
1985), and were approved by the research and ethics
committee of Kurdistan University of Medical Sciences,
Sanandaj, Iran.
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Morphine sulfate (Temad, Tehran, Iran) [1 mg/kg, intra-
peritoneal (i.p.), 10 mg/kg, i.p., 100 mg/kg, i.p.] was dis-
solved in normal saline and injected using 1-mL insulin
syringes. Simvastatin (Sigma-Aldrich, Germany) [5 mg/kg,
per os (p.o.), 10 mg/kg, p.o., and 20 mg/kg, p.o.] was
dissolved in vehicle (dimethyl sulfoxide þ propylene glycol
400, 1:1); it was orally administered using gavage syringes.
Naloxone (Darou Pakhsh, Tehran, Iran) 4 mg/kg was also
dissolved in normal sterile saline. The solutions were
freshly prepared on the day of the experiment.
Experimental groups
The experimental groups are described in Table 1.
Induction of tolerance to the analgesic effect of
morphine
Morphine (10 mg/kg, i.p.) was injected once a day to
induce tolerance to the analgesic effect. This dose was
adapted from previous studies, and was found to cause
profound analgesia.26 Morphine was injected daily 30 mi-
nutes after simvastatin administration.
Morphine antinociception assessment
Nociception was assessed by a plantar test apparatus
(Hargreaves Method; IITC Life Science Inc., Woodland Hills,
CA, USA). The rats were placed in a transparent plastic cage
(20 cm long  10 cm wide  12 cm high) and allowed to
acclimatize to the cage for 30 minutes in a temperature-
controlled room (23  2C) prior to the behavioral test.
Afterwards, the cage was placed on a glass plate above the
plantar test apparatus and a movable noxious heat sourceTable 1 The experimental groups.
Study sections Treatment groups (n Z 8 per group
Tolerance evaluation
groups
Sal (1 mL/kg, i.p.) þ Sim Veh (1 mL
Mor (10 mg/kg, i.p.) þ Sim Veh (1 m
Mor (10 mg/kg, i.p.) þ Sim (5 mg/k
Mor (10 mg/kg, i.p.) þ Sim (10 mg/
Mor (10 mg/kg, i.p.) þ Sim (20 mg/
Groups for doseeresponse curves
Animals received opposite treatmen
on the 19th day, in separate groups
of Mor (1mg/kg, i.p. or 10 mg/kg, i.
were administered to generate anal
curves
Withdrawal symptoms
evaluation groups
Sal (1 mL/kg, i.p.) þ Sim Veh (1 mL
Mora þ Sim Veh (1 mL/kg, p.o.)
Mora þ Sim (5 mg/kg, p.o.)
Mora þ Sim (10 mg/kg, p.o.)
Mora þ Sim (20 mg/kg, p.o.)
Sim (20 mg/kg, p.o.)
i.p. Z intraperitoneal; Mor Z morphine; p.o. Z per os (oral
sulfoxide þ polyethylene glycol 400, 1:1.
a Additive doses of Mor were used as described in the section Inducwas directly placed under the plantar surface of the hind
paw. When it was activated, the apparatus used a contin-
uous beam stimulus to the plantar surface, and a distinctive
paw withdrawal reflex was elicited. In addition, a timer was
automatically activated with the beginning of lighting. It is
worth noting that the paw withdrawal latency was consid-
ered as the time between the paw exposure to the radiant
heat and the paw withdrawal. The baseline paw withdrawal
latency was determined for each rat as the average of three
measurements, and the intensity of the light was also
adjusted so that the baseline latencies were 2e3 seconds.
In this regard, the thermal exposure was interrupted after
10 seconds (cut-off) to avoid tissue damage. Next, the hind
paws were alternately tested with a 2-minute interval be-
tween consecutive tests. Two measurements of the latency
were averaged for each hind paw in each test session. The
latency of the withdrawal response was expressed as the
percentage of the maximal possible effect (%MPE) accord-
ing to the following equation:
%MPEZ½Post drug latencyðsÞ  baseline latencyðsÞ=½cut
 off valueðsÞ  baseline latencyðsÞ  100
The baseline latency was determined once per day (the
average of three measurements) for each rat prior to the
daily injection of morphine (10 mg/kg) or vehicle. Thirty
minutes after the injection, the post-drug latency was
measured. The %MPE was then calculated for that day. The
experiments were continued until there was no significant
difference in the %MPE between the drug-treated group
(the tolerant animals) and the vehicle-treated group.27
Evaluation of global analgesic effect
The area under the curve (AUC) of the %MPE was calculated
in order to evaluate the global analgesic effect and to allow
a comparison of the effects from different behavioral tests.)
/kg, p.o.)
L/kg, p.o.)
g, p.o.)
kg, p.o.)
kg, p.o.)
ts for 19 days;
logarithmic doses
p. or 100 mg/kg, i.p.)
gesic doseeresponse
Sal (1 mL/kg, i.p.) þ Sim Veh
(1 mL/kg, p.o.)
Mor (10 mg/kg, i.p.) þ Sim Veh
(1 mL/kg, p.o.)
Mor (10 mg/kg, i.p.) þ Sim
(20 mg/kg, p.o.)
/kg, p.o.)
); Sal Z saline; Sim Z simvastatin; Sim Veh Z dimethyl
tion of morphine dependence.
Table 2 Weighing factors (WFs) of different withdrawal
signs.
Behavior WF
Jumping 4
Abdominal writhing 5
Wet-dog shaking 5
Genital grooming 10
Rearing 20
Figure 1 The analgesic effect of daily administration of
morphine (10 mg/kg, i.p.) in the control group (Mor þ Sim
Veh). Tolerance to the analgesic effect of morphine was star-
ted on the 7th day and completed on the 19th day when there
were no significant differences in the %MPE between the con-
trol and the (Sal þ Sim Veh) groups. Each bar represents the
mean of %MPE  SEM for eight rats. y and Y represent the day
of tolerance onset and completion, respectively.
i.p. Z intraperitoneal; Mor Z morphine; %MPE Z percentage
maximal possible effect; SalZ saline; SEMZ standard error of
the mean; Sim Veh Z simvastatin vehicle.
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from the observed values.
Evaluation of tolerance induction
Groups of rats received the simvastatin vehicle or the
morphine þ simvastatin vehicle or the
morphine þ simvastatin (the most effective dose) once per
day for 19 days in order to evaluate the induction of toler-
ance. On the 19th day (the day of morphine tolerance in the
control group), the logarithmic doses of the morphine
(1 mg/kg, i.p., 10 mg/kg, i.p., 100 mg/kg, i.p.) were
administrated to generate the analgesic doseeresponse
curves (according to the experimental groups of Table 1). In
the analgesic doseeresponse curves, the morphine anti-
nociceptive 50% effective dose (ED50) values for each of the
drug groups were derived by the linear regression of the %
MPE of the logarithmic doses of the morphine.28
Induction of morphine dependence
The additive doses of the morphine were subcutaneously
administered for 9 days in order to induce dependency as
follows: Day 1: 5 mg/kg/12 h, Day 2 and Day 3: 10 mg/kg/
12 h, Day 4 and Day 5: 15 mg/kg/12 h, Day 6 and Day 7:
20 mg/kg/12 h, and Day 8 and Day 9: 25 mg/kg/12 h. On the
9th day, only the morning dose of morphine was injected.
This morphine administration protocol was shown to pro-
duce a high degree of dependency in the rats. In addition,
the simvastatin was administered on the 9th day 60 minutes
prior to the injection of naloxone and 30 minutes after the
last dose of morphine.29
Induction of morphine withdrawal and behavioral
sign measurement
Naloxone (4 mg/kg, i.p.) was injected on the 9th day, 1 hour
after the morning dose of morphine, in order to induce
withdrawal symptoms. The naloxone dose was selected
according to a previous study.29 A behavioral assessment
was then carried outdopioid withdrawal signs including
jumping, wet-dog shaking, abdominal writhing, genital
grooming, and rearing were scored over a 60-minute period
following the naloxone injection. Afterwards, the animals
were individually examined in a clear plexiglass chamber
(Plexiran, Iran) (50 cm  25 cm  15 cm) that was placed in
another dark chamber to prevent environmental perturba-
tions. A digital camera connected to a recording computer
was also placed on the inner chamber to show the rats’
behaviors simultaneously. The reactions of each animal
were then assessed by an observer who was not aware of
the nature of the treatment received by the animal. The
behavior of each animal was evaluated by the same
observer. All the signs including jumping, wet-dog shake,
abdominal writing, and rearing were counted during the
evaluation time, whereas the duration of the behavior was
recorded in minutes for genital grooming. As previously
described, the score of each behavior was divided by
weighing the factor attributed to it (Table 2), and the re-
sults were added to attain a total withdrawal score (TWS)for each animal; the TWS was used as an index of the
withdrawal intensity.30
Data analysis
The obtained data from the plantar tests was defined as the
mean of %MPE  SEM for eight rats per groups. The data of
the withdrawal signs was expressed as mean  SEM. The
Student t test or repeated measures analysis of variance
(ANOVA) followed by the Bonferroni test was used to
analyze the statistical significance in two or multiple
comparisons, respectively. A p value <0.05 was considered
to be significant in all analyses.
Results
Morphine tolerance to the antinociceptive effect
The results showed that tolerance started on the 7th day,
during which the analgesic effect of morphine significantly
decreased in the control group (morphine þ simvastatin
vehicle). In addition, the administration of morphine
(10 mg/kg, i.p.) once a day for 19 days induced tolerance to
the antinociceptive effect of this drug in the control group
Figure 3 Plantar test latencies and %MPE of the logarithmic
doses of morphine (1, 10, 100 mg/kg, i.p.) administered on the
19th day. Each point represents the mean  SEM for eight rats.
Different morphine doses were administered on the 19th day
that showed a significant shift to the right in the dos-
eeresponse curve and the antinociceptive ED50 values in ani-
mals treated with Mor þ Sim Veh compared to those that
received the Sim Veh or Mor þ Sim (20 mg/kg, p.o.).
ED50 Z 50% effective dose; Mor Z morphine; %
MPE Z percentage maximal possible effect; p.o. Z per os
(oral); Sal Z saline; SEM Z standard error of the mean;
Sim Z simvastatin; Sim Veh Z simvastatin vehicle.
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there were no significant differences between the control
group and the vehicle-treated animals; therefore, this day
was considered as the date of morphine tolerance
completion.
Effect of simvastatin on morphine-induced
tolerance to the analgesic effect
The results indicated that simvastatin (10, 20 mg/kg, p.o.)
delayed the onset of morphine-induced tolerance for 3 days
and 5 days, respectively (Fig. 2). Fig. 2 also reveals that
simvastatin (5 mg/kg, p.o., 10 mg/kg, p.o., 20 mg/kg, p.o.)
postponed tolerance completion for 1 day, 4 days, and 5
days, respectively. In addition, the doseeresponse curve
showed a significant shift to the left in the animals who
received morphine þ simvastatin compared to those that
received morphine þ simvastatin vehicle (control group). A
significant shift to the left in the ED50 was also seen in the
morphine þ simvastatin (20 mg/kg, p.o.; 42.5 mg) treated
groups compared to the control animals (50.5 mg; Fig. 3).
The results also showed that the most effective dose of
simvastatin (20 mg/kg, p.o.) had no significant analgesic
effect (the data was not shown). However, simvastatin
(20 mg/kg, p.o.) had the greatest AUC of the %MPE (1143.7)
in comparison with the control group (966) or simvastatin
(5 mg/kg, p.o.; 1007) or simvastatin (10 mg/kg, p.o.; 998;
Table 3).
Effect of simvastatin on morphine withdrawal signs
The results showed that the systemic administration of
simvastatin (5 mg/kg, p.o., 10 mg/kg, p.o., 20 mg/kg, p.o.)
decreased withdrawal signs significantly. The findingsFigure 2 The effect of daily systemic administration of
simvastatin (5, 10, 20 mg/kg, p.o.) on onset and completion of
tolerance to the analgesic effect of morphine. Each bar rep-
resents the mean of %MPE  SEM for eight rats. y and Y
represent the day of tolerance onset and completion, respec-
tively. A p value <0.05 was considered significant in all ana-
lyses. *p < 0.05 when compared with the control group
(Mor þ Sim Veh) for the onset of tolerance. **p < 0.05 when
compared with the control group (Mor þ Sim Veh) for the
completion of tolerance. Mor Z morphine; %
MPE Z percentage maximal possible effect; p.o. Z per os
(oral); SEM Z standard error of the mean; Sim Z simvastatin;
Sim Veh Z simvastatin vehicle.indicated that simvastatin attenuated the number of
jumping and abdomen writing events and the duration of
genital grooming compared to the control (dependent)
animals (Fig. 4) whereas the number of wet-dog shaking
and rearing events did not significantly change in all groups.
In addition, the results in Fig. 5 indicate that the adminis-
tration of simvastatin resulted in a significant decrease in
the TWS in comparison with the control group (p < 0.001).Discussion
The results of the present study showed that chronic
administration of morphine for 19 days induced toleranceTable 3 The global analgesic effect of morphine in the
control and treatment groups during 23 days of
experimentation.a
Group AUC SEM
Sal þ Sim Veh 33.59*** 5
Mor þ Sim Veh 956.9 12
Mor þ Sim 5 mg/kg 1007* 14
Mor þ Sim 10 mg/kg 998.6* 10
Mor þ Sim 20 mg/kg 1143.6** 12
*p < 0.05, **p < 0.01, ***p < 0.001, when compared to the
control (Mor þ Sim Veh) group.
AUC Z area under the curve; Mor Z morphine; %
MPE Z percentage of maximal possible effect; Sim
Veh Z simvastatin vehicle.
a The AUC of the %MPE was calculated for each group for 23
days. To calculate the AUC, the trapezoidal rule was used. One-
way analysis of variance (ANOVA) followed by Tukey’s test were
used to analyze the differences between the control and
treatment groups. A p value <0.05 was considered to be sig-
nificant in all analyses.
Figure 4 The effects of simvastatin (5, 10, 20 mg/kg, p.o.) on naloxone (4 mg/kg)-induced withdrawal signs in morphine-
dependent rats that received additive doses of morphine (5, 10, 15, 20, 25 mg/kg/12 h) for 9 days. Data are defined as
mean  SEM. *p < 0.05, **p < 0.01, ***p < 0.001 different from the control group (M þ Sim Veh). M Z morphine; p.o. Z per os
(oral); Sal Z saline; SEM Z standard error of the mean; Sim Z simvastatin; Sim Veh Z simvastatin vehicle.
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simvastatin (5 mg/kg, p.o., 10 mg/kg, p.o., 20 mg/kg, p.o.)
decreased the development of this tolerance through
shifting on the 1st day of onset and the completion of
tolerance to the right. The results also indicated that there
was a significant shift to the left in the doseeresponse
curve and a decrease in the antinociceptive ED50 of
morphine for the animals who received morphine andFigure 5 The effects of simvastatin (5, 10, 20 mg/kg, p.o.)
on the naloxone (4 mg/kg)-induced TWS in morphine-
dependent rats. The data is defined as mean  SEM.
***p < 0.001 different from the control group (Mor þ Sim Veh).
Mor Z morphine; p.o. Z per os (oral); Sal Z saline;
SEM Z standard error of the mean; Sim Z simvastatin; Sim
Veh Z simvastatin vehicle; TWS Z total withdrawal score.simvastatin (20 mg/kg) compared to the control. This
means that the simvastatin prevented the shifting of the
doseeresponse curve and the ED50 to the right. In addition,
the administration of simvastatin (20 mg/kg) in combina-
tion with the morphine represented an important higher
analgesic effect in the global analgesia analysis (the AUC
measurement). However, the administration of simvastatin
by itself had no important analgesic effect; this suggests
that the simvastatin did not simply enhance the morphine
analgesia through an additive mechanism.
Among the possible mechanisms of opioid tolerance and
dependency, neural toxicity is known to have a key role. In
this respect, previous studies showed that both morphine
tolerance and the associated neuronal apoptosis shared a
common cellular mechanism.14 In line with these findings,
it was recently reported that neuroprotective agents such
as donepezil, minocycline, riluzole, and MK801 (an NMDA
receptor antagonist) blocked both the tolerance and the
apoptosis.14,31e34 This means that neuroprotective drugs
are reasonable agents for the prevention of morphine
tolerance.
Recently, simvastatin was found to have anti-
inflammatory effects and it was reported that the intake
of statins was associated with a decrease in the incidence
of neurodegenerative diseases such as AD, PD, and multiple
sclerosis.15,16,19
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ment induces microglia and astrocyte activation,6e8 which
results in an increase in the release of proinflammatory
cytokines such as TNF-a, IL-1b, IL-6, prostaglandins, excit-
atory amino acids (glutamate and aspartate), and nitric
oxide.9,10 These inflammatory products can lead to induc-
tion of morphine tolerance and dependence.8,9,11 However,
there is accumulating evidence that agents with anti-
inflammatory effects are effective in suppressing opioid
antinociceptive tolerance. Pentoxifylline and minocycline
are examples of such agents that have efficacy in sup-
pression of glial activation and attenuation of morphine-
induced tolerance in animal models.35
Recently, Chen et al36 reported that simvastatin
attenuated formalin-induced nociceptive responses
through inhibiting microglial RhoA and the p38 mitogen-
activated protein kinase activation. Inactivation of the
RhoAep38 signaling pathway might be a pharmacologic
target for treating microglia-directed central nervous
system inflammation and chronic pain conditions.36 More-
over, Mika et al37 reported that the effect of minocycline
on morphine tolerance was related to microglia. Their
results provided the evidence that systemic administration
of minocycline in mice influences the effectiveness of
morphine and delays the development of morphine toler-
ance through attenuation of microglial activation and its
markers.37
Simvastatin also protects neurons from NMDA-induced
neuronal death by up to 70%. These data show that the
reduction of cholesterol levels by simvastatin protects
neurons from NMDA-induced damage, probably via reducing
the association of NMDA receptors to lipid rafts.22,23 By
contrast, the activation of NMDA receptors initiates intra-
cellular pathways that lead to apoptotic cell death.
Glutamate and NMDA cause intracellular Ca2þ influx, acti-
vation of Ca2þ-dependent enzymes such as nitric oxide
synthase, and production of toxic oxygen radicals that lead
to cell death.38
On the contrary, Bo¨sel et al39 believe that the protective
properties of atorvastatin occur independently of HMG-CoA
reductase inhibition because cotreatment with mevalonate
or other isoprenoids does not reverse or attenuate the
neuroprotection. They reported that atorvastatin attenu-
ated the glutamate-induced increase of intracellular cal-
cium that was associated with modulation of NMDA
receptor function.39
Based on the results of our study, simvastatin decreased
the withdrawal signs and the total withdrawal score by it-
self. This effect might be due to the inhibitory action of
simvastatin on NMDA receptors because previous findings
indicated that NMDA receptor antagonists or glutamate
release inhibitors attenuated morphine withdrawal symp-
toms.26,40,41 The use of simvastatin as a single dose was
supported by Carloni et al42 who reported that it provided
protection from hypoxic ischemic brain damage and that
the neuroprotection was in part enabled by preserving Akt
and stimulating cAMP response element-binding protein
(CREB) phosphorylation in neuronal cells.
In conclusion, simvastatin as a neuroprotective agent
prevented morphine-induced tolerance to the analgesic
effects. In addition, simvastatin attenuated naloxone-
induced withdrawal symptoms. These effects werepossibly related to the neuroprotective properties of sim-
vastatin including the prevention of glutamate release and
the inhibition of microglial cell activation.Acknowledgments
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